Methods and compositions for treating hypoglycemic disorders
This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism comprising administering to the subject an effective amount of a peptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO:1.
2. The method of claim 1 , wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof.
3. The method of claim 1 , wherein the peptide is administered subcutaneously.
4. The method of claim 1 , wherein the peptide is administered intravenously.
5. The method of claim 1 , wherein the peptide is administered by infusion.
6. The method of claim 1 , wherein the peptide is administered using a pump.
7. The method of claim 1 , wherein the congenital hyperinsulinism is associated with a genetic abnormality or mutation.
8. The method of claim 7 , wherein the genetic abnormality is associated with a mutation in a gene selected from the group consisting of a gene encoding a sulfonylurea receptor (SUR-1), a gene encoding glucokinase (GCK), a gene encoding glutamate dehydrogenase (GLUD-1), and a gene encoding mitochondrial enzyme short-chain 3-hydroxyacyl-CoA dehydrogenase (HADHSC).
9. The method of claim 1 , wherein the subject has congenital hyperinsulinism, and wherein the subject is over 10 years of age.
10. The method of claim 9 , wherein the subject is over 30 years of age.
11. The method of claim 1 , wherein the peptide is administered to a subject from 2 years to 10 years of age.